Investors
SEED ROUND NOW OPEN — CLOSING Q3 2026
Investing in the first therapy designed to restore brain structure in Alzheimer’s.
Interested in the first therapy designed to restore brain structure in Alzheimer’s?
COAT™ represents a paradigm shift in neurological rehabilitation, standing as the world’s first adaptive olfactory stimulation therapy specifically designed to directly target and restore the olfactory–hippocampal pathway.
Seed round
$1.5M target
Planned close Q3 2026
Series A Round
$10M target
Starting Q4 2026
NIH Funding & Program Support
Clinical Trial Registrations
Peer-Reviewed COAT™ Studies
NIH Science Highlight
Our Team
Deep neuroscience, regulatory, and commercialization experience.
COAT is built and advised by a team spanning clinical neuroscience, medtech commercialization, regulatory strategy, and academic memory-disorder research.
Evaristus Nwulia, MD
Founder & CEO
Evon Medics, Director, Blueprint NeuroTech Incubator
Sumeet Seth, MBA
Chief Commercialization Officer
CEO, Trulogik
Paula Rutledge
Fund-Raising Advisor
CEO, Legacy MedSearch
Sebastian Seiguer, JD, MBA
Chief Legal & Business Advisor
CEO, Scene Health
Bryant Moore, Ph.D.
Senior Advisor, Strategic Partnerships
EvON Medics
Vamsi Reddy, MSE
Global Head of Product Development
EvON Medics
Charles Nwaokobia, MBA
COO & President
EvON Medics
Holly Cotter, RAC, RCC-MDR
Lead Regulatory Advisor
Founder, White Lamb Regulatory Services
Thomas Obisesan, MD, MPH
Chief Medical Officer
Prof. & Director, Memory Center & AVP Research, Howard University
Externally validated. Globally recognized.
NIH Science Highlight
Featured COAT™ research
Presented
COAT™
July 12-15, 2026 London
Presenting COAT™
November 2026 Boston
Press Coverage — COAT™
BioSpace
EvON Medics Data Demonstrates Digital Olfactory Therapy Reverses Gray Matter Loss in Key Brain Regions
PR Newswire
EvON Medics Data Demonstrates Digital Olfactory Therapy Reverses Gray Matter Loss…
Data Room
Request Investor Data Room Meeting
Get access to full clinical trial data, the complete pitch deck, cap table summary, IP portfolio, and financial model. We review every request and typically respond within 2 business days.
- Complete investor pitch deck
- IP portfolio & regulatory status
- Financial model & use of funds detail